Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) said on Friday that it has submitted an extension application to the European Medicines Agency (EMA) for a new subcutaneous formulation of Opdivo (nivolumab).
The application seeks approval across multiple previously approved adult solid tumour indications.
Validation by the EMA initiates the centralised review process.
Subcutaneous Opdivo offers faster administration times compared to the intravenous formulation and could improve the patient experience.
Phase 3 trial data supported the application, demonstrating non-inferiority in efficacy and safety.
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes